Median Technologies announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mid-caps listed on Euronext markets in Amsterdam, Brussels, Dublin, Lisbon and Paris, in the Tech sector (i.e., Life Sciences, Clean Tech and Technology, Media & Telecom).
Read moreMedian Technologies appoints Oern Stuge MD, MBA, to its Board of Directors. Oern Stuge brings to Median his tremendous expertise in the life sciences industry as well as his unique vision and experience in enterprise development including Go to Market strategy and Medtech company growth.
Read moreMedian Technologies announces today the results of a preliminary retrospective study on the evaluation of the risk of recurrence for patients with primary liver cancer (HCC – hepatocellular carcinoma) based on a non-invasive biomarker.
Read moreMedian Technologies (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19. Revenue of €2.8m, +47% compared with the first quarter of 2019; Order backlog of €44.4m, +€6.1m compared with December 31, 2019; Median Technologies at the service of biopharmaceutical companies involved in Covid-19 clinical trials.
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]